Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,793,280
  • Shares Outstanding, K 2,532,900
  • Annual Sales, $ 22,465 M
  • Annual Income, $ 3,001 M
  • 36-Month Beta 0.60
  • Price/Sales 4.18
  • Price/Cash Flow 11.09
  • Price/Book 6.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.38 +8.12%
on 06/28/18
37.37 -0.54%
on 07/20/18
+1.04 (+2.88%)
since 06/20/18
3-Month
34.38 +8.12%
on 06/28/18
37.37 -0.54%
on 07/20/18
+1.83 (+5.18%)
since 04/20/18
52-Week
28.43 +30.74%
on 07/27/17
37.37 -0.54%
on 07/20/18
+3.28 (+9.68%)
since 07/20/17

Most Recent Stories

More News
Ironwood Begins New Phase III Study to Expand Linzess Label

Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.

IRWD : 20.02 (-0.20%)
AZN : 37.17 (+0.38%)
AGN : 171.79 (-0.92%)
TARO : 112.94 (-0.72%)
Novartis Looks to Exit Antibacterial, Antiviral Program

Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

AZN : 37.17 (+0.38%)
AGN : 171.79 (-0.92%)
NVS : 82.27 (+1.82%)
PFE : 37.33 (-0.08%)
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

CTIC : 2.35 (+3.52%)
AZN : 37.17 (+0.38%)
JNJ : 125.85 (-0.07%)
MRK : 62.52 (+0.02%)
ABBV : 88.91 (-1.16%)
PFE : 37.33 (-0.08%)
BMY : 56.71 (+0.30%)
Biogen's Alzheimer Disease Candidate Succeeds in Phase II

Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

AZN : 37.17 (+0.38%)
JNJ : 125.85 (-0.07%)
LLY : 88.47 (-1.07%)
BIIB : 358.71 (+0.17%)
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.

AZN : 37.17 (+0.38%)
CLVS : 47.87 (+1.76%)
TSRO : 39.24 (-2.46%)
PFE : 37.33 (-0.08%)
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

AZN : 37.17 (+0.38%)
JNJ : 125.85 (-0.07%)
MRK : 62.52 (+0.02%)
ADMP : 3.80 (+4.11%)
NVS : 82.27 (+1.82%)
GSK : 41.87 (+2.90%)
BMY : 56.71 (+0.30%)
AstraZeneca's Two New Cancer Drugs Get Approval in Japan

AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.

AZN : 37.17 (+0.38%)
MRK : 62.52 (+0.02%)
ABBV : 88.91 (-1.16%)
PFE : 37.33 (-0.08%)
Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress

The Dow endured a turbulent week, marked by lingering trade tensions.

FOXA : 46.00 (-1.39%)
AZN : 37.17 (+0.38%)
JPM : 111.28 (+1.26%)
INTC : 51.91 (-0.13%)
WBA : 64.98 (+0.08%)
NKE : 76.96 (+0.01%)
GS : 231.69 (+0.90%)
PFE : 37.33 (-0.08%)
UNH : 252.70 (-0.09%)
DIS : 111.48 (-0.58%)
BA : 354.90 (-0.12%)
Blog Exposure - AstraZeneca's LYNPARZA(R) Reports Encouraging Results from Phase-III 1st-Line SOLO-1 Trial for Advanced Ovarian Cancer

LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want access to our free research report on AstraZeneca PLC (NYSE: ), all you need to do is sign up now by clicking the following link as the Company's...

AZN : 37.17 (+0.38%)
AstraZeneca/Merck's Lynparza Betters Survival in Phase III

AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.

AZN : 37.17 (+0.38%)
MRK : 62.52 (+0.02%)
CLVS : 47.87 (+1.76%)
TSRO : 39.24 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 37.58
1st Resistance Point 37.37
Last Price 37.17
1st Support Level 36.96
2nd Support Level 36.76

See More

52-Week High 37.37
Last Price 37.17
Fibonacci 61.8% 33.95
Fibonacci 50% 32.90
Fibonacci 38.2% 31.85
52-Week Low 28.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar